NCT06128915 The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses
| NCT ID | NCT06128915 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | State University of New York at Buffalo |
| Condition | Aging |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-01-08 |
| Primary Completion | 2027-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 60 participants in total. It began in 2024-01-08 with a primary completion date of 2027-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study focuses on the role of neutrophils in shaping the adaptive immune response to the anti-pneumococcal vaccine Prevnar-13 in young and elderly adults.
Eligibility Criteria
Inclusion Criteria: * Both sexes * Have not been vaccinated with any licensed or experimental pneumococcal vaccine * Ages 21-40; and ≥65. Individuals \>60 years old will also be recruited in case we find no unvaccinated people ≥65 years old * Free of acute infections within the last 2 weeks * Did not take any anti-inflammatory medicine in the last week * Did not ingest alcohol in the last 24 hours * Ability and willingness to provide consent Exclusion Criteria: * Previous vaccination with any licensed or experimental pneumococcal vaccine * Known hypersensitivity to vaccination and vaccine components * Immune deficiency * Use of immune-modulating or suppressive drugs * Malignancies within the last 2 years * Known hematological, rheumatic and inflammatory diseases * Known chronic infections * Poorly controlled chronic cardiovascular and metabolic conditions * Pregnancy * Dementia
Contact & Investigator
Elsa N Bou Ghanem, PhD
PRINCIPAL INVESTIGATOR
University at Buffalo
Frequently Asked Questions
Who can join the NCT06128915 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Aging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06128915 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06128915 currently recruiting?
Yes, NCT06128915 is actively recruiting participants. Contact the research team at elsaboug@buffalo.edu for enrollment information.
Where is the NCT06128915 trial being conducted?
This trial is being conducted at Buffalo, United States.
Who is sponsoring the NCT06128915 clinical trial?
NCT06128915 is sponsored by State University of New York at Buffalo. The principal investigator is Elsa N Bou Ghanem, PhD at University at Buffalo. The trial plans to enroll 60 participants.